Topical instillation of cell-penetrating peptide-conjugated melphalan blocks metastases of retinoblastoma

Biomaterials. 2022 May:284:121493. doi: 10.1016/j.biomaterials.2022.121493. Epub 2022 Apr 1.

Abstract

Retinoblastoma is the most common primary intraocular malignancy in infancy with a metastases-related death risk. However, a safe and convenient treatment without enucleation is still an unmet clinical need. In this work, a cell-penetrating peptide, 89WP, was conjugated with melphalan (89WP-Mel), which achieved high tumor inhibition effects as intravitreally injected melphalan via topical instillation for the first time. Notably, the "outside-in" diffusion of instilled 89WP-Mel created a protective shield surrounding the eye, efficiently preventing tumor metastases, while the mice treated with intravitreally injected melphalan suffered more brain metastases related death. The ocular absorption of 89WP-conjugated melphalan and other small molecules, both hydrophobic and hydrophilic, occurred via non-corneal pathway with high safety and a prolonged residence duration in retina up to 24 h. The present work paves a new avenue for simultaneous intraocular tumor inhibition and extraocular metastases prevention in a safe and convenient way via topical instillation.

Keywords: Brain metastases; Cell-penetrating peptide; Eye drops; Melphalan; Retinoblastoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents, Alkylating
  • Cell-Penetrating Peptides* / therapeutic use
  • Melphalan / therapeutic use
  • Mice
  • Retinal Neoplasms* / drug therapy
  • Retinal Neoplasms* / pathology
  • Retinoblastoma* / drug therapy
  • Retinoblastoma* / metabolism
  • Retinoblastoma* / pathology

Substances

  • Antineoplastic Agents, Alkylating
  • Cell-Penetrating Peptides
  • Melphalan